The tumour glyco-code as a novel immune checkpoint for immunotherapy.
| Title: | The tumour glyco-code as a novel immune checkpoint for immunotherapy. |
|---|---|
| Authors: | RodrÍguez E; Department of Molecular Cell Biology and Immunology, VU University Medical Center, Amsterdam, Netherlands.; Schetters STT; Department of Molecular Cell Biology and Immunology, VU University Medical Center, Amsterdam, Netherlands.; van Kooyk Y; Department of Molecular Cell Biology and Immunology, VU University Medical Center, Amsterdam, Netherlands. |
| Source: | Nature reviews. Immunology [Nat Rev Immunol] 2018 Mar; Vol. 18 (3), pp. 204-211. Date of Electronic Publication: 2018 Feb 05. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't; Review |
| Language: | English |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101124169 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-1741 (Electronic) Linking ISSN: 14741733 NLM ISO Abbreviation: Nat Rev Immunol |
| Imprint Name(s): | Original Publication: London, UK : Nature Pub. Group, [c2001- |
| MeSH Terms: | Immunotherapy/*methods ; Neoplasm Proteins/*immunology ; Neoplasms/*immunology ; Neoplasms/*metabolism ; Programmed Cell Death 1 Receptor/*metabolism ; T-Lymphocytes/*immunology; Lectins/immunology ; Lectins/metabolism ; Neoplasm Proteins/metabolism ; Neoplasms/therapy ; Polysaccharides/immunology ; Tumor Escape/immunology ; Tumor Microenvironment/immunology ; Glycosylation ; Humans |
| Abstract: | Tumour growth is accompanied by tumour evasion of the immune system, a process that is facilitated by immune checkpoint molecules such as programmed cell death protein 1 (PD1). However, the role of tumour glycosylation in immune evasion has mostly been overlooked, despite the fact that aberrant tumour glycosylation alters how the immune system perceives the tumour and can also induce immunosuppressive signalling through glycan-binding receptors. As such, specific glycan signatures found on tumour cells can be considered as a novel type of immune checkpoint. In parallel, glycosylation of tumour proteins generates neo-antigens that can serve as targets for tumour-specific T cells. In this Opinion article, we highlight how the tumour 'glyco-code' modifies immunity and suggest that targeting glycans could offer new therapeutic opportunities. |
| References: | Adv Cancer Res. 2015;126:1-10. (PMID: 25727144); J Exp Med. 2014 Jun 30;211(7):1465-83. (PMID: 24935259); Proc Natl Acad Sci U S A. 2016 Mar 22;113(12):3329-34. (PMID: 26941238); Nat Immunol. 2002 Nov;3(11):991-8. (PMID: 12407406); Br J Cancer. 2013 Feb 19;108(3):662-7. (PMID: 23322207); Nat Rev Immunol. 2007 Oct;7(10):790-802. (PMID: 17853902); Sci Transl Med. 2017 Jul 12;9(398):null. (PMID: 28701476); Nat Rev Immunol. 2014 Oct;14(10):653-66. (PMID: 25234143); Mol Oncol. 2014 May;8(3):753-65. (PMID: 24656965); Blood. 2015 Oct 15;126(16):1911-20. (PMID: 26272216); Science. 2015 Jan 23;347(6220):1260419. (PMID: 25613900); Adv Cancer Res. 2017;134:85-116. (PMID: 28110657); Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15029-34. (PMID: 14657390); Cancer Res. 2005 Jul 1;65(13):5935-44. (PMID: 15994972); Proc Natl Acad Sci U S A. 2016 Sep 13;113(37):10304-9. (PMID: 27551071); Nat Immunol. 2006 Nov;7(11):1200-8. (PMID: 16998493); Mol Cell. 2017 Dec 7;68(5):827-829. (PMID: 29220650); Nat Immunol. 2008 Jun;9(6):593-601. (PMID: 18490910); Nature. 2005 Oct 27;437(7063):1252. (PMID: 16251947); Nat Genet. 2005 Jul;37(7):692-700. (PMID: 15924140); Front Oncol. 2016 May 13;6:109. (PMID: 27242953); Oncoimmunology. 2014 Oct 31;4(8):e970462. (PMID: 26405564); Proc Natl Acad Sci U S A. 2010 May 11;107 Suppl 2:8939-46. (PMID: 20445087); Proc Natl Acad Sci U S A. 2014 Sep 30;111(39):E4066-75. (PMID: 25118277); Anal Chem. 2018 Jan 2;90(1):208-224. (PMID: 29049885); Science. 2015 Apr 3;348(6230):56-61. (PMID: 25838373); Front Immunol. 2017 Aug 02;8:912. (PMID: 28824637); Cancer Immunol Res. 2017 May;5(5):376-384. (PMID: 28314751); Cancer Cell. 2017 Jun 12;31(6):804-819.e7. (PMID: 28609658); Glycobiology. 2011 Sep;21(9):1121-4. (PMID: 21932452); Nat Immunol. 2007 Aug;8(8):825-34. (PMID: 17589510); Mol Cell Proteomics. 2015 Jun;14(6):1616-29. (PMID: 25813380); Biomolecules. 2012 Oct 11;2(4):435-66. (PMID: 24970145); Nat Commun. 2016 Aug 30;7:12632. (PMID: 27572267); Sci Rep. 2016 May 20;6:26451. (PMID: 27198045); Nat Rev Cancer. 2015 Sep;15(9):540-55. (PMID: 26289314); Nat Commun. 2014 Oct 03;5:5074. (PMID: 25278262); Clin Breast Cancer. 2003 Feb;3 Suppl 4:S134-8. (PMID: 12620150); Mol Cancer Ther. 2013 Oct;12(10):1935-46. (PMID: 23974695); Nature. 2017 Jan 18;541(7637):321-330. (PMID: 28102259); Cell. 2017 Feb 9;168(4):613-628. (PMID: 28187284); J Exp Med. 2002 Dec 2;196(11):1435-46. (PMID: 12461079); J Clin Invest. 2014 Apr;124(4):1810-20. (PMID: 24569453); Cancer Cell. 2004 Mar;5(3):241-51. (PMID: 15050916); Proc Natl Acad Sci U S A. 2004 May 25;101(21):8132-7. (PMID: 15141079); Cell. 2015 Sep 24;163(1):39-53. (PMID: 26406370); Trends Immunol. 2017 May;38(5):358-372. (PMID: 28385520); Nat Med. 2015 May;21(5):431-9. (PMID: 25951530); J Biol Chem. 1997 Nov 21;272(47):29721-8. (PMID: 9368041); Clin Chim Acta. 2014 Nov 1;437:183-6. (PMID: 25086284); J Cell Biol. 2010 May 31;189(5):843-58. (PMID: 20498016); Nat Rev Drug Discov. 2005 Jun;4(6):477-88. (PMID: 15931257); Trends Immunol. 2013 Oct;34(10):482-6. (PMID: 23608151); J Leukoc Biol. 2013 Aug;94(2):315-23. (PMID: 23744646); Oncotarget. 2015 Sep 22;6(28):26278-90. (PMID: 26172302); J Immunol. 2010 Aug 1;185(3):1383-92. (PMID: 20574007); Nat Immunol. 2016 Nov;17 (11):1273-1281. (PMID: 27595232); Cancer Cell. 2017 Nov 13;32(5):639-653.e6. (PMID: 29136507); Nat Immunol. 2009 Sep;10(9):981-91. (PMID: 19668220); Proc Natl Acad Sci U S A. 2013 Aug 20;110(34):E3152-61. (PMID: 23912186); Oncotarget. 2016 Feb 23;7(8):8771-82. (PMID: 26741508); Nat Rev Gastroenterol Hepatol. 2013 Oct;10(10):607-20. (PMID: 23856888); Science. 2016 May 6;352(6286):658-60. (PMID: 27151852); Proteomics. 2016 Apr;16(8):1257-65. (PMID: 26841254); Oncologist. 2011;16(8):1092-100. (PMID: 21572124); Nature. 2017 Sep 28;549(7673):538-542. (PMID: 28959962); Methods Mol Biol. 2017;1503:235-264. (PMID: 27743371); Immunity. 2013 Jul 25;39(1):1-10. (PMID: 23890059); Nat Rev Urol. 2013 Feb;10(2):99-107. (PMID: 23318363); Curr Opin Immunol. 2017 Apr;45:8-15. (PMID: 28088061); Oncotarget. 2017 Jul 10;8(40):68012-68025. (PMID: 28978092); Immunity. 2016 Jun 21;44(6):1444-54. (PMID: 27332733); EMBO J. 2011 Jun 28;30(15):3173-85. (PMID: 21712812) |
| Substance Nomenclature: | 0 (Lectins); 0 (Neoplasm Proteins); 0 (PDCD1 protein, human); 0 (Polysaccharides); 0 (Programmed Cell Death 1 Receptor) |
| Entry Date(s): | Date Created: 20180206 Date Completed: 20190821 Latest Revision: 20190821 |
| Update Code: | 20260130 |
| DOI: | 10.1038/nri.2018.3 |
| PMID: | 29398707 |
| Database: | MEDLINE |
Journal Article; Research Support, Non-U.S. Gov't; Review